Palonosetron Versus Ramosetron for the Prevention of Postoperative Nausea and Vomiting

Incheon St.Mary's Hospital100 enrolled

Overview

Ramosetron and palonosetron are more recently developed 5-hydroxytryptamine type 3 receptor antagonists and this randomized double blind study was designed to compare efficacy of ramosetron and palonosetron to prevent postoperative nausea and vomiting. Investigator hypothesized that palonosetron would have stronger and longer lasting antiemetic effect compared with ramosetron and evaluated the patients for the first 48 hours after surgery.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

PREVENTION

Masking

QUADRUPLE

Enrollment

100

Conditions

Postoperative Nausea and Vomiting

Interventions

palonosetronDRUG

0.075mg immediately before induction of anesthesia

RamosetronDRUG

0.3mg immediately before induction of anesthesia

Eligibility

Sex: FEMALEMin age: 20 Years

Medical Language ↔ Plain English

Inclusion Criteria: * ASA Physical Status 1 or 2 * Elective gynaecological laparoscopic surgery of ≥ 1h duration Exclusion Criteria: * Anti-emetics, steroids, or psychoactive medications within 24 h of study initiation * Vomiting or retching in the 24 h preceding surgery * Cancer chemotherapy within 4 weeks or emetogenic radiotherapy within 8 weeks before study entry * Ongoing vomiting from gastrointestinal disease

Locations (1)

Incheon St. Mary's hospital

Incheon, South Korea

Outcomes

Primary Outcomes

Incidence of postoperative nausea and vomiting for 48 hours after surgery

Time frame: for 48 hours after surgery

Secondary Outcomes

severity of nausea for 48 hours after surgery

Time frame: for 48 hours after surgery

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.